Jared Winoker, MD
Urology · Baltimore, MDNPI 1972920908
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $49,997 of the $61,601 with a category attached, or 81.2%. Calyxo, Inc. accounts for 76.4% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $37,002, more than ten times the $1,635 reported in 2021. Among urology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $535.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calyxo, Inc.$47K
- Boston Scientific$6K
- Ambu Inc.$6K
- Ambu A/s$2K
- Novo Nordisk Health Care AG$114
- Travere Therapeutics, Inc.$8
What the payments were for
- Consulting fees$49,99781%
- Speaking & faculty fees$8001%
- Travel & lodging$5,7879%
- Food & beverage$5,0088%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calyxo, Inc. | 60 | $47,065 |
| Boston Scientific | 45 | $6,129 |
| Ambu Inc. | 4 | $5,884 |
| Ambu A/s | 2 | $2,400 |
| Novo Nordisk Health Care AG | 1 | $114 |
| Travere Therapeutics, Inc. | 3 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CVAC Aspiration System$37,869
- CVAC$8,667
- GENERAL KIDNEY STONE DISEASE$2,819
- LITHOCLAST$301
- GENERAL - THERAPIES$128
How this compares
$61,601 in reported general payments places this provider in the 95th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 50 | $22,437 |
| Tamsulosin Hcl | 69 | $764 |
| Oxybutynin Chloride ErOxybutynin Chloride | 26 | $635 |
| Finasteride | 35 | $578 |
| Potassium Citrate ErPotassium Citrate | 13 | $446 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 17 | $282 |
Paid to pharmacies, not to this prescriber.
Other urology in Baltimore
- Benjamin LowentrittBaltimore$549K
- Amin HeratiBaltimore$160K
- Max KatesBaltimore$139K
- Arthur BurnettBaltimore$132K
- Aaron WeinbergBaltimore$106K
- Brian MatlagaBaltimore$99K
- Ronald TutroneBaltimore$89K
- Jason LevyBaltimore$55K
- Arvin GeorgeBaltimore$46K
- Christian PavlovichBaltimore$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.